|
1
|
Smyth EC, Nilsson M, Grabsch HI, van
Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Karimi P, Islami F, Anandasabapathy S,
Freedman ND and Kamangar F: Gastric cancer: Descriptive
epidemiology, risk factors, screening, and prevention. Cancer
Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Harris AL: Hypoxia-a key regulatory factor
in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lu X and Kang Y: Hypoxia and
hypoxia-inducible factors: Master regulators of metastasis. Clin
Cancer Res. 16:5928–5935. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Poellinger L and Johnson RS: HIF-1 and
hypoxic response: The plot thickens. Curr Opin Genet Dev. 14:81–85.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Majmundar AJ, Wong WJ and Simon MC:
Hypoxia-inducible factors and the response to hypoxic stress. Mol
Cell. 40:294–309. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Semenza GL, Jiang BH, Leung SW, Passantino
R, Concordet JP, Maire P and Giallongo A: Hypoxia response elements
in the aldolase A, enolase 1, and lactate dehydrogenase A gene
promoters contain essential binding sites for hypoxia-inducible
factor 1. J Biol Chem. 271:32529–32537. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Comerford KM, Wallace TJ, Karhausen J,
Louis NA, Montalto MC and Colgan SP: Hypoxia-inducible
factor-1-dependent regulation of the multidrug resistance (MDR1)
gene. Cancer Res. 62:3387–3394. 2002.PubMed/NCBI
|
|
9
|
Ide T, Kitajima Y, Miyoshi A, Ohtsuka T,
Mitsuno M, Ohtaka K, Koga Y and Miyazaki K: Tumor-stromal cell
interaction under hypoxia increases the invasiveness of pancreatic
cancer cells through the hepatocyte growth factor/c-Met pathway.
Int J Cancer. 119:2750–2759. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hara S, Nakashiro K, Klosek SK, Ishikawa
T, Shintani S and Hamakawa H: Hypoxia enhances c-Met/HGF receptor
expression and signaling by activating HIF-1alpha in human salivary
gland cancer cells. Oral Oncol. 42:593–598. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Forsythe JA, Jiang BH, Iyer NV, Agani F,
Leung SW, Koos RD and Semenza GL: Activation of vascular
endothelial growth factor gene transcription by hypoxia-inducible
factor 1. Mol Cell Biol. 16:4604–4613. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stoeltzing O, McCarty MF, Wey JS, Fan F,
Liu W, Belcheva A, Bucana CD, Semenza GL and Ellis LM: Role of
hypoxia-inducible factor 1alpha in gastric cancer cell growth,
angiogenesis, and vessel maturation. J Natl Cancer Inst.
96:946–956. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vaupel P, Mayer A and Höckel M: Tumor
hypoxia and malignant progression. Methods Enzymol. 381:335–354.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kitajima Y and Miyazaki K: The critical
impact of HIF-1a on gastric cancer biology. Cancers (Basel).
5:15–26. 2013. View Article : Google Scholar
|
|
15
|
Rankin EB and Giaccia AJ: Hypoxic control
of metastasis. Science. 352:175–180. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singh D, Srivastava SK, Chaudhuri TK and
Upadhyay G: Multifaceted role of matrix metalloproteinases (MMPs).
Front Mol Biosci. 2:192015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brown PD: Matrix metalloproteinases in
gastrointestinal cancer. Gut. 43:161–163. 1998. View Article : Google Scholar
|
|
19
|
Gialeli C, Theocharis AD and Karamanos NK:
Roles of matrix metalloproteinases in cancer progression and their
pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar
|
|
20
|
Page-McCaw A, Ewald AJ and Werb Z: Matrix
metalloproteinases and the regulation of tissue remodelling. Nat
Rev Mol Cell Biol. 8:221–233. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McCawley LJ and Matrisian LM: Matrix
metalloproteinases: They're not just for matrix anymore! Curr Opin
Cell Biol. 13:534–540. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boire A, Covic L, Agarwal A, Jacques S,
Sherifi S and Kuliopulos A: PAR1 is a matrix metalloprotease-1
receptor that promotes invasion and tumorigenesis of breast cancer
cells. Cell. 120:303–313. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shintani T, Kusuhara Y, Daizumoto K,
Dondoo TO, Yamamoto H, Mori H, Fukawa T, Nakatsuji H, Fukumori T,
Takahashi M and Kanayama H: The involvement of hepatocyte growth
Factor-MET-Matrix metalloproteinase 1 signaling in bladder cancer
invasiveness and proliferation. Effect of the MET inhibitor,
cabozantinib (XL184), on bladder cancer cells. Urology.
101:169.e7–169.e13. 2017. View Article : Google Scholar
|
|
24
|
Wang J, Liu D, Zhou W, Wang M, Xia W and
Tang Q: Prognostic value of matrix
metalloprotease-1/protease-activated receptor-1 axis in patients
with prostate cancer. Med Oncol. 31:9682014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang QM, Lv L, Tang Y, Zhang L and Wang
LF: MMP-1 is overexpressed in triple-negative breast cancer tissues
and the knockdown of MMP-1 expression inhibits tumor cell malignant
behaviors in vitro. Oncol Lett. 17:1732–1740. 2019.PubMed/NCBI
|
|
26
|
Yamamoto H, Itoh F, Iku S, Adachi Y,
Fukushima H, Sasaki S, Mukaiya M, Hirata K and Imai K: Expression
of matrix metalloproteinases and tissue inhibitors of
metalloproteinases in human pancreatic adenocarcinomas:
Clinicopathologic and prognostic significance of matrilysin
expression. J Clin Oncol. 19:1118–1127. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pittayapruek P, Meephansan J, Prapapan O,
Komine M and Ohtsuki M: Role of matrix metalloproteinases in
photoaging and photocarcinogenesis. Int J Mol Sci. 17:8682016.
View Article : Google Scholar :
|
|
28
|
Wang K, Zheng J, Yu J, Wu Y, Guo J, Xu Z
and Sun X: Knockdown of MMP-1 inhibits the progression of
colorectal cancer by suppressing the PI3K/Akt/c-myc signaling
pathway and EMT. Oncol Rep. 43:1103–1112. 2020.PubMed/NCBI
|
|
29
|
Grimm M, Lazariotou M, Kircher S, Stuermer
L, Reiber C, Höfelmayr A, Gattenlöhner S, Otto C, Germer CT and von
Rahden BH: MMP-1 is a (pre-)invasive factor in Barrett-associated
esophageal adenocarcinomas and is associated with positive lymph
node status. J Transl Med. 8:992010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Eiró N, González LO, Atienza S,
González-Quintana JM, Beridze N, Fernandez-Garcia B,
Pérez-Fernández R, García-Caballero T, Schneider J and Vizoso FJ:
Prediction of metastatic breast cancer in non-sentinel lymph nodes
based on metalloprotease-1 expression by the sentinel lymph node.
Eur J Cancer. 49:1009–1017. 2013. View Article : Google Scholar
|
|
31
|
Bianco BC, Scotti FM, Vieira DS, Biz MT,
Castro RG and Modolo F: Immunohistochemical expression of matrix
metalloproteinase-1, matrix metalloproteinase-2 and matrix
metalloproteinase-9, myofibroblasts and Ki-67 in actinic cheilitis
and lip squamous cell carcinoma. Int J Exp Pathol. 96:311–318.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hanrahan K, O'Neill A, Prencipe M, Bugler
J, Murphy L, Fabre A, Puhr M, Culig Z, Murphy K and Watson RW: The
role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in
mediating docetaxel-resistant prostate cancer. Mol Oncol.
11:251–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lassig AAD, Joseph AM, Lindgren BR and
Yueh B: Association of oral cavity and oropharyngeal cancer
biomarkers in surgical drain fluid with patient outcomes. JAMA
Otolaryngol Head Neck Surg. 143:670–678. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim M, Kim HJ, Choi BY, Kim JH, Song KS,
Noh SM, Kim JC, Han DS, Kim SY and Kim YS: Identification of
potential serum biomarkers for gastric cancer by a novel
computational method, multiple normal tissues corrected
differential analysis. Clin Chim Acta. 413:428–433. 2012.
View Article : Google Scholar
|
|
35
|
Altadill A, Rodriguez M, Gonzalez LO,
Junquera S, Corte MD, González-Dieguez ML, Linares A, Barbón E,
Fresno-Forcelledo M, Rodrigo L and Vizoso FJ: Liver expression of
matrix metalloproteases and their inhibitors in hepatocellular
carcinoma. Dig Liver Dis. 41:740–748. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Du X, Wang S, Lu J, Cao Y, Song N, Yang T,
Dong R, Zang L, Yang Y, Wu T and Li J: Correlation between
MMP1-PAR1 axis and clinical outcome of primary gallbladder
carcinoma. Jpn J Clin Oncol. 41:1086–1093. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mizrachi A, Koren R, Hadar T, Yaniv E,
Morgenstern S and Shvero J: Expression of MMP-1 in invasive
well-differentiated thyroid carcinoma. Eur Arch Otorhinolaryngol.
268:131–135. 2011. View Article : Google Scholar
|
|
38
|
Ozden F, Saygin C, Uzunaslan D, Onal B,
Durak H and Aki H: Expression of MMP-1, MMP-9 and TIMP-2 in
prostate carcinoma and their influence on prognosis and survival. J
Cancer Res Clin Oncol. 139:1373–1382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Murray GI, Duncan ME, O'Neil P, McKay JA,
Melvin WT and Fothergill JE: Matrix metalloproteinase-1 is
associated with poor prognosis in oesophageal cancer. J Pathol.
185:256–261. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Murray GI, Duncan ME, O'Neil P, Melvin WT
and Fothergill JE: Matrix metalloproteinase-1 is associated with
poor prognosis in colorectal cancer. Nat Med. 2:461–462. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Inoue T, Yashiro M, Nishimura S, Maeda K,
Sawada T, Ogawa Y, Sowa M and Chung KH: Matrix metalloproteinase-1
expression is a prognostic factor for patients with advanced
gastric cancer. Int J Mol Med. 4:73–77. 1999.PubMed/NCBI
|
|
42
|
Wang J, Ye C, Lu D, Chen Y, Jia Y, Ying X,
Xiong H, Zhao W, Zhou J and Wang L: Matrix metalloproteinase-1
expression in breast carcinoma: A marker for unfavorable prognosis.
Oncotarget. 8:91379–91390. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu M, Hu Y, Zhang MF, Luo KJ, Xie XY, Wen
J, Fu JH and Yang H: MMP1 promotes tumor growth and metastasis in
esophageal squamous cell carcinoma. Cancer Lett. 377:97–104. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Langenskiöld M, Ivarsson ML, Holmdahl L,
Falk P, Kåbjörn-Gustafsson C and Angenete E: Intestinal mucosal
MMP-1-a prognostic factor in colon cancer. Scand J Gastroenterol.
48:563–569. 2013. View Article : Google Scholar
|
|
45
|
Fujimoto D, Hirono Y, Goi T, Katayama K
and Yamaguchi A: Prognostic value of protease-activated receptor-1
(PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer.
Anticancer Res. 28:847–854. 2008.PubMed/NCBI
|
|
46
|
Tanaka T, Kitajima Y, Miyake S, Yanagihara
K, Hara H, Nishijima-Matsunobu A, Baba K, Shida M, Wakiyama K,
Nakamura J and Noshiro H: The apoptotic effect of HIF-1α inhibition
combined with glucose plus insulin treatment on gastric cancer
under hypoxic conditions. PLoS One. 10:e01372572015. View Article : Google Scholar
|
|
47
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
48
|
Karlsson R, Pedersen ED, Wang Z and
Brakebusch C: Rho GTPase function in tumorigenesis. Biochim Biophys
Acta. 1796:91–98. 2009.PubMed/NCBI
|
|
49
|
Martin DN, Boersma BJ, Yi M, Reimers M,
Howe TM, Yfantis HG, Tsai YC, Williams EH, Lee DH, Stephens RM, et
al: Differences in the tumor microenvironment between
African-American and European-American breast cancer patients. PLoS
One. 4:e45312009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hu C, Zhou H, Liu Y, Huang J, Liu W, Zhang
Q, Tang Q, Sheng F, Li G and Zhang R: ROCK1 promotes migration and
invasion of non-small-cell lung cancer cells through the
PTEN/PI3K/FAK pathway. Int J Oncol. 55:833–844. 2019.PubMed/NCBI
|
|
51
|
Fei F, Qu J, Zhang M, Li Y and Zhang S:
S100A4 in cancer progression and metastasis: A systematic review.
Oncotarget. 8:73219–73239. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cho JY, Chung HC, Noh SH, Roh JK, Min JS
and Kim BS: High level of urokinase-type plasminogen activator is a
new prognostic marker in patients with gastric carcinoma. Cancer.
79:878–883. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zheng HC, Sun JM, Li XH, Yang XF, Zhang YC
and Xin Y: Role of PTEN and MMP-7 expression in growth, invasion,
metastasis and angiogenesis of gastric carcinoma. Pathol Int.
53:659–666. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Valacca C, Tassone E and Mignatti P:
TIMP-2 Interaction with MT1-MMP Activates the AKT Pathway and
protects tumor cells from apoptosis. PLoS One. 10:e01367972015.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Pasquini G and Giaccone G: C-MET
inhibitors for advanced non-small cell lung cancer. Expert Opin
Investig Drugs. 27:363–375. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wen B, Xu LY and Li EM: LOXL2 in cancer:
Regulation, downstream effectors and novel roles. Biochim Biophys
Acta Rev Cancer. 1874:1884352020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Poplineau M, Schnekenburger M, Dufer J,
Kosciarz A, Brassart-Pasco S, Antonicelli F, Diederich M and
Trussardi-Régnier A: The DNA hypomethylating agent,
5-aza-2'-deoxycytidine, enhances tumor cell invasion through a
transcription-dependent modulation of MMP-1 expression in human
fibrosarcoma cells. Mol Carcinog. 54:24–34. 2015. View Article : Google Scholar
|
|
58
|
Poplineau M, Dufer J, Antonicelli F and
Trussardi-Regnier A: Epigenetic regulation of proMMP-1 expression
in the HT1080 human fibrosarcoma cell line. Int J Oncol.
38:1713–1718. 2011.PubMed/NCBI
|
|
59
|
Zhang T, Fan J, Wu K, Zeng J, Sun K, Guan
Z, Wang X, Hiesh JT and He D: Roles of HIF-1α in a novel optical
orthotopic spontaneous metastatic bladder cancer animal model. Urol
Oncol. 30:928–935. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhou ZH, Ji CD, Xiao HL, Zhao HB, Cui YH
and Bian XW: Reorganized Collagen in the tumor microenvironment of
gastric cancer and its association with prognosis. J Cancer.
8:1466–1476. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yin Y, Zhao Y, Li AQ and Si JM: Collagen:
A possible prediction mark for gastric cancer. Med Hypotheses.
72:163–165. 2009. View Article : Google Scholar
|
|
62
|
Gao SY, Li J, Qu XY, Zhu N and Ji YB:
Downregulation of Cdk1 and cyclinB1 expression contributes to
oridonin-induced cell cycle arrest at G2/M phase and growth
inhibition in SGC-7901 gastric cancer cells. Asian Pac J Cancer
Prev. 15:6437–6441. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kanthan R, Fried I, Rueckl T, Senger JL
and Kanthan SC: Expression of cell cycle proteins in male breast
carcinoma. World J Surg Oncol. 8:102010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wang Y, Zhou X, Shan B, Han J, Wang F, Fan
X, Lv Y, Chang L and Liu W: Downregulation of microRNA-33a promotes
cyclin-dependent kinase 6, cyclin D1 and PIM1 expression and
gastric cancer cell proliferation. Mol Med Rep. 12:6491–6500. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Liu FY, Wang LP, Wang Q, Han P, Zhuang WP,
Li MJ and Yuan H: MiR-302b regulates cell cycles by targeting CDK2
via ERK signaling pathway in gastric cancer. Cancer Med.
5:2302–2313. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Chu DZ, Lang NP, Thompson C, Osteen PK and
Westbrook KC: Peritoneal carcinomatosis in nongynecologic
malignancy. A prospective study of prognostic factors Cancer.
63:364–367. 1989.
|
|
67
|
Yonemura Y, Kawamura T, Bandou E,
Tsukiyama G, Endou Y and Miura M: The natural history of free
cancer cells in the peritoneal cavity. Recent Results Cancer Res.
169:11–23. 2007.PubMed/NCBI
|
|
68
|
del Casar JM, Corte MD, Alvarez A, García
I, Bongera M, González LO, García-Muñiz JL, Allende MT, Astudillo A
and Vizoso FJ: Lymphatic and/or blood vessel invasion in gastric
cancer: Relationship with clinicopathological parameters,
biological factors and prognostic significance. J Cancer Res Clin
Oncol. 134:153–161. 2008. View Article : Google Scholar
|
|
69
|
Kubo H, Kitajima Y, Kai K, Nakamura J,
Miyake S, Yanagihara K, Morito K, Tanaka T, Shida M and Noshiro H:
Regulation and clinical significance of the hypoxia-induced
expression of ANGPTL4 in gastric cancer. Oncol Lett. 11:1026–1034.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Kosaka Y, Mimori K, Fukagawa T, Ishikawa
K, Etoh T, Katai H, Sano T, Watanabe M, Sasako M and Mori M:
Clinical significance of molecular detection of matrix
metalloproteinase-1 in bone marrow and peripheral blood in patients
with gastric cancer. Ann Surg Oncol. 19(Suppl 3): S430–S437. 2012.
View Article : Google Scholar
|
